A 25-year-old woman with a severe migraine begins to use a migraine specific agent, eletriptan (40 mg/d). One month later, she had oligomenorrhea and galactorrhea. We ruled out all causes of hyperprolactinemia. To our knowledge, this is the first published postmarketing case report of eletriptan-induced hyperprolactinemia, presented as oligomenorrhea and galactorrhea in a patient. The Naranjo probability scale indicates a probable relationship between hyperprolactinemia and eletriptan therapy. ©2012 Dustri-Verlag Dr. K. Feistle.
|Number of pages||1|
|Journal||International Journal of Clinical Pharmacology and Therapeutics|
|Publication status||Published - Dec 2012|
- Adverse affect